公开(公告)号：US20230070752A1

公开(公告)日：2023-03-09

申请号：US17273637

申请日：2020-08-19

Applicant: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Ho Min KIM ,  Jae-Hee CHUNG ,  Eui-Cheol SHIN ,  Seon-Hui HONG

IPC: C07K14/555 ,  A61P3/10 ,  A61P31/12 ,  A61P35/00 ,  A61K38/00

Abstract: Disclosed are a novel interferon lambda variant produced through structure-based glycoengineering and a method of producing the same. The novel interferon lambda variant and the method of producing the same exhibit remarkably improved production and yield in mammalian cell lines using structural information-based glycoengineering even through conventional purification protocols, and exhibit significantly improved therapeutic properties such as stability, half-life, and fraction of functional proteins during treatment, compared to wild-type interferon lambda. In addition, the novel interferon lambda variant and the method of producing the same according to the present invention have higher antiviral activity and interferon-stimulated gene (ISG)-inducing activity than wild-type interferon lambda, and thus are useful for the prevention and treatment of immune-related diseases such as cancer and autoimmune diseases as well as various viral infections such as infection with SARS-CoV-2 (COVID-19).